Peptide vendor tracker
2024 — 202618 EVENTS TRACKED · LAST VERIFIED 2026-10-16Since late 2024 the peptide supply market has been reshaped by warning-letter waves, criminal prosecutions, a port seizure, a brand-name manufacturer's trade complaint, and payment-network pressure. This page documents what happened: every event sourced, evidence-graded, and dated. It is not a vendor guide — it does not rank, recommend, or evaluate vendors, and it links only to regulators', courts', and press sources.
Visa notices to underwriting banks precede Chameleon Peptides closure
Chameleon Peptides closes after Visa sends notices to its underwriting banks questioning whether the company's sales were reaching only research customers, according to an incumbent vendor-directory account citing an industry email. This is the first entry in this catalog in which a payment network's action, rather than a regulator's or a court's, is reported to have immediately preceded a seller's closure.
Eternal Peptides closes
Eternal Peptides ceases operations in a closure reported as voluntary. The only accessible account is an incumbent vendor-directory article; no regulator action or primary record has been located for this closure.
FDA warns 'research use only' peptide sellers
The FDA issues warning letters to at least four sellers marketing peptides 'for research use only': NuScience Peptides LLC, Royal Peptides, Peptide Partners, and Peak Peptides. The NuScience letter (MARCS-CMS 733652), captured verbatim, cites nine products — including a 'GLP-2 Tirz Peptide', retatrutide, and tesamorelin blends — as unapproved new drugs under section 505(a), issued over the signature of the Director of CDER's Office of Unapproved Drugs and Labeling Compliance. A possible fifth letter to another seller was reported but unconfirmed at capture time.
Paradigm Peptides operators sentenced — 70 and 16 months
Owner Matthew Kawa is sentenced to 70 months in prison and a co-defendant to 16 months, following guilty pleas to distributing unapproved drugs and illegal importation, in the U.S. Attorney's case (Northern District of Indiana) that ended Paradigm Peptides. The DOJ release's title and date are confirmed via search results and an accessible secondary report; the release body was not machine-fetchable at verification. The forfeiture amount (reported at roughly $5 million) and the product-adulteration details (forged lab certificates; testosterone found in products) trace to secondary summaries and ship at the lowest grade, not as primary-verified facts.
Strate Labs winds down after Eli Lilly ITC default
Strate Labs announces a voluntary wind-down, citing a shifted regulatory landscape. The company was the defaulted respondent in Eli Lilly's International Trade Commission complaint over tirzepatide, with a cease-and-desist order issued against it. This is the first entry in this catalog in which a brand-name manufacturer's private action, rather than an FDA or DOJ action, preceded a peptide seller's exit.
FDA warns 25 more telehealth companies over compounded-GLP-1 promotion
The FDA sends approximately 25 additional warning letters to telehealth companies over compounded GLP-1 promotion, extending the March 2026 telehealth warning campaign. Documented via legal-industry analysis and the FDA's own social accounts; the letter list had not been re-located on fda.gov at verification time.
Gram Peptides warning letter (MARCS-CMS 721806)
The FDA issues a warning letter to Gram Peptides (MARCS-CMS 721806) following a review of its website beginning January 2026, citing unapproved new drugs. The letter is on fda.gov; its URL was not retained at capture time, so the letter is cited by its MARCS-CMS control number.
Peptide Sciences shuts down
Peptide Sciences, a US research-chemical peptide supplier, posts a closure notice (around 2pm ET) and ceases operations. The closure is voluntary, and no specific enforcement action against the company has been confirmed. Reported context: an estimated ~$7.4M in online sales in December 2025 alone, failed third-party retesting of 37 retatrutide samples, and GLP-1 litigation exposure.
FDA warns 30 telehealth companies over compounded-GLP-1 marketing
The FDA issues warning letters to 30 telehealth companies over false or misleading claims about compounded GLP-1 drugs — a wave aimed at promotion by clinics and platforms rather than at compounders themselves.
Science.bio ceases operations
Science.bio ceases operations, stating that it will refund outstanding orders and offering no detailed explanation. The closure reads as voluntary; no enforcement action against the company appears in any primary source located for this catalog.
CBP Cincinnati intercepts 5,000+ unapproved peptide vials
U.S. Customs and Border Protection officers in Cincinnati foil the smuggling of more than 5,000 unapproved peptide vials, interdicting the shipment at the port before domestic distribution. Located via CBP's newsroom; the specific release was surfaced through search results during verification.
FDA sends 55+ warning letters to compounded-GLP-1 sellers
The FDA issues more than 55 warning letters to online sellers of compounded GLP-1 agonists, citing 503A/503B compounding failures — the largest single letter wave in this catalog. An example letter to 'GLP-1 Solution' dated September 9, 2025 is on fda.gov; the wave total is documented by trade press.
Criminal prosecutions with $1.79M–$3M+ forfeitures
PeptaHub's earlier regulatory coverage reported federal prosecutions of peptide sellers concluding with forfeitures ranging from $1.79 million to more than $3 million. The underlying DOJ releases were not re-located during the October 2026 verification pass; this entry is carried on that previously published in-house record pending re-location of the primaries.
Federal raid takes Amino Asylum offline
Federal agents raid Amino Asylum's warehouse operations across Tennessee and Kentucky; the site goes offline around June 17, 2025 and operations cease. The founders are reported, by a later secondary account, to have pled guilty (July 2026); a relaunch attempt under a different name was reported but not confirmed.
Warrior Labz operator sentenced (Vermont)
Jeremy Brown, operator of Warrior Labz, is sentenced for selling unapproved drugs online, in a DOJ / FDA Office of Criminal Investigations prosecution out of Vermont. Documented via a justice.gov release surfaced in search results; the release URL was not retained at capture time.
Four thinly documented 2025 closures
Royal Research, Peptide Tech Labs, American Research Labs, and Unchained Compounds stop operating during 2025 under what an incumbent vendor-directory article describes as regulatory pressure. These closures are thinly sourced: the directory article is the only located account, dates are not published, and no primary record has been located for any of the four. They are carried at the lowest evidence grade and named here only as market events.
First warning-letter wave hits gray-market sellers
The FDA issues warning letters to Summit Research Peptides, Prime Peptides, Xcel Peptides, and SwissChems for selling unapproved new drugs — the earliest warning-letter wave in this catalog. The letters are on fda.gov; their URLs were not retained during the October 2026 pass, so this entry carries the in-house record.
Paradigm Peptides closes as owner is charged
Paradigm Peptides ceases operations after its owner is charged in the Northern District of Indiana case that ends with the July 2026 sentencings. The case's full arc — from these 2024 charges to a 70-month sentence — spans the entire period this tracker covers.
Enforcement in this market no longer arrives only as an FDA letter. It now reaches sellers through the criminal courts, the ports, a manufacturer's trade complaint, and the payment rail itself — and it produces voluntary exits in its wake.
The administrative front door of enforcement. The FDA has run distinct letter waves against the peptide market since December 2024: gray-market sellers, compounded-GLP-1 sellers (55+ letters, September 2025), telehealth marketers (March and June 2026), and 'research use only' sellers (August 2026). A warning letter is not itself legal enforcement, but it puts the recipient on the record.
Criminal cases brought by the Department of Justice and the FDA's Office of Criminal Investigations: the Warrior Labz sentencing (February 2025), the Amino Asylum raid (June 2025), the September 2025 forfeiture round, and the Paradigm Peptides case, whose 70-month sentence in July 2026 is the longest in this catalog. This is the channel that carries prison time and asset forfeiture.
Customs and Border Protection stops unapproved peptide shipments at ports of entry before they reach domestic distribution — such as the December 2025 Cincinnati interception of more than 5,000 vials. Interdiction acts on shipments at the border rather than on a seller.
Brand-name manufacturers pursuing their own enforcement actions. Eli Lilly's International Trade Commission complaint over tirzepatide produced a cease-and-desist order against a defaulted respondent, Strate Labs, which wound down in July 2026. Enforcement pressure now arrives through private actions, not only through regulators.
Card networks and their underwriting banks withdrawing payment processing. In September 2026, Visa notices to underwriting banks — questioning whether a seller's customers were really researchers — were reported to have preceded the closure of Chameleon Peptides. On that account, no regulator action was involved: the withdrawal of the payment rail itself did the work.
Voluntary closures under pressure: Science.bio (January 2026), Peptide Sciences (March 2026), Eternal Peptides (September 2026), and others. An exit is not an enforcement action — for Peptide Sciences and Science.bio, no specific enforcement action has been confirmed — but the exit wave is part of the same market contraction the enforcement channels drive.
"Peptide supplier" means three regulatorily distinct things. Which one a seller is determines which regime applies and where enforcement lands — a regulatory description, with no vendors named.
FDA-approved products and telehealth prescribers
Peptides that are approved drugs — or lawfully compounded versions of them — prescribed through licensed medical channels, including telehealth platforms.
Full FDA drug approval and marketing rules. Compounded versions are permitted only under the statutory conditions of sections 503A/503B — the conditions cited in the September 2025 55+ letter wave.
On marketing, not on the products' existence: the March and June 2026 letter waves targeted telehealth companies' false or misleading compounded-GLP-1 claims.
503A–503B compounders
State-licensed compounding pharmacies (503A) and FDA-registered outsourcing facilities (503B) that prepare customized drug products.
Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Bulk substances must appear on the 503A Bulks List or fall within enforcement discretion; placement in Category 2 of the interim list means a substance is not on the Bulks List and so is not compounding-eligible.
Warning letters and related administrative action, concentrated in the September 2025 55+ letter wave over compounded GLP-1s and the shortage-driven compounding deadlines that preceded it.
Gray-market 'research use only' sellers
Unlicensed online sellers marketing peptides as chemicals 'for research use only', not for human consumption.
No specific licensing regime — which is the point of contention: the FDA's August 2026 letters cite section 505(a) — unapproved new drugs — against 'research use only' sellers whose marketing the agency treated as drug marketing.
Every channel in this tracker has reached this layer: letters, raids, prosecutions with prison time, port seizures, an ITC order, and payment-network exclusion. Buying from this layer carries legal risk for buyers that varies by jurisdiction.
Yes — but 'shut down' compresses several different things. Since December 2024, this tracker has cataloged dated events across five enforcement channels: FDA warning-letter waves, DOJ prosecutions with prison sentences and reported forfeitures, a CBP port seizure, Eli Lilly's ITC action, and one closure reported to have followed payment-network pressure. Alongside those, several sellers closed voluntarily (Science.bio, Peptide Sciences, Eternal Peptides). The documented pattern is escalating, targeted enforcement concentrated on gray-market 'research use only' sellers and compounded-GLP-1 marketing.
The FDA's position, stated in the August 2026 warning letters, is that peptides sold 'for research use only' are unapproved new drugs when marketed in ways that imply human use. Buying them for personal use carries legal risk for buyers that varies by jurisdiction, and these are not approved drugs made under any approved-drug quality system — in the Paradigm Peptides case, lab certificates were reported to have been forged. This page documents the enforcement record; it is not legal advice. For substance-by-substance status, see our peptide legal status guide and per-compound regulatory status tracker.
Three different things. Peptide Sciences shut down voluntarily on March 6, 2026; no specific enforcement action against it has been confirmed, though failed third-party retatrutide tests and GLP-1 litigation exposure were reported as context. Amino Asylum was raided by federal agents in June 2025 and its founders are reported to have pled guilty — that one was criminal enforcement. Science.bio ceased operations voluntarily on January 27, 2026, offering refunds on outstanding orders without a detailed explanation.
No. The FDA removed 12 peptides from Category 2 of the interim 503A list on April 15, 2026, but removal from Category 2 is not legalization: it does not place a substance on the 503A Bulks List and does not make it eligible for compounding. The July 2026 PCAC vote recommending six peptides is advisory, not a rule. Unapproved new drugs remain unapproved. See our peptide legal status guide and the per-compound regulatory status tracker for what actually changed.
Related: peptide legal status guide · per-compound regulatory status · FDA action timeline
These rules are policy, and this page exists only because of them. They extend the editorial rules behind our per-compound regulatory status tracker and legal status guide.
- Every event carries at least one source with an evidence grade. Primary= the regulator's or court's own record (fda.gov, justice.gov, cbp.gov, federalregister.gov, ITC dockets). Secondary = a named press report or legal-industry analysis. Reported= a single-source or uncorroborated account — an incumbent vendor-directory closure article, a community thread, or PeptaHub's own previously published regulatory record carried while a primary is re-located. That grade is an honest floor, not an endorsement.
- Where a specific document URL was not retained at capture time, the source is named — with its MARCS-CMS control number where one exists — rather than linked to a homepage.
- No ranking, scoring, or preferred order of any operating vendor, and no comparison of living vendors. Operating vendors appear only as named enforcement-action subjects (a warning-letter recipient is a public FDA fact) or as aggregate counts. This page answers what happened; it never answers where to go now.
- No outbound links to vendor or vendor-directory domains of any kind, including nofollow. Some sources are therefore named without links — that is deliberate.
- Closures are documented as market and regulatory events, not as consumer problems to route around. Buying gray-market peptides carries legal risk for buyers; that framing stays attached wherever the gray market is described.
- Outcomes are never inferred. Pleas, forfeitures, and closure circumstances ship only at the grade their sources support, or not at all.
- Last verified 2026-10-16 · reviewed weekly. The stamp moves only after every entry has been rechecked against its sources.
Open dataset (CC BY 4.0), in the same format as our State of Peptides 2026 dataset: dataset.json · dataset.csv
The peptide supply market is contracting, and the record of why is still being written. Every claim here carries its evidence. This page is rechecked weekly.